These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 7797782)

  • 41. Consumer groups look to improve adverse event reporting systems.
    Vastag B
    J Natl Cancer Inst; 2005 Dec; 97(24):1804-5. PubMed ID: 16368939
    [No Abstract]   [Full Text] [Related]  

  • 42. FDA attempting to overcome major roadblocks in monitoring drug safety.
    Zielinski SL
    J Natl Cancer Inst; 2005 Jun; 97(12):872-3. PubMed ID: 15956645
    [No Abstract]   [Full Text] [Related]  

  • 43. Today's FDA.
    Slater EE
    N Engl J Med; 2005 Jan; 352(3):293-7. PubMed ID: 15659733
    [No Abstract]   [Full Text] [Related]  

  • 44. Comparisons of Food and Drug Administration and European Medicines Agency risk management implementation for recent pharmaceutical approvals: report of the International Society for Pharmacoeconomics and outcomes research risk benefit management working group.
    Lis Y; Roberts MH; Kamble S; J Guo J; Raisch DW
    Value Health; 2012 Dec; 15(8):1108-18. PubMed ID: 23244814
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Regulatory experts debate FDA's authority.
    Young D
    Am J Health Syst Pharm; 2007 May; 64(9):910, 912. PubMed ID: 17468140
    [No Abstract]   [Full Text] [Related]  

  • 46. Drug safety. Gaps in the safety net.
    Couzin J
    Science; 2005 Jan; 307(5707):196-8. PubMed ID: 15653480
    [No Abstract]   [Full Text] [Related]  

  • 47. Fulfilling the Mandate of the US Food and Drug Administration's Accelerated Approval Pathway: The Need for Reforms.
    Gyawali B; Ross JS; Kesselheim AS
    JAMA Intern Med; 2021 Oct; 181(10):1275-1276. PubMed ID: 34254981
    [No Abstract]   [Full Text] [Related]  

  • 48. MEDWATCH: the new FDA medical products reporting program.
    Kennedy DL
    Respir Care; 1993 Oct; 38(10):1077-80. PubMed ID: 10145891
    [No Abstract]   [Full Text] [Related]  

  • 49. How many deaths occur annually from adverse drug reactions in the United States?
    Chyka PA
    Am J Med; 2000 Aug; 109(2):122-30. PubMed ID: 10967153
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Neuropsychiatric adverse effects of oseltamivir in the FDA Adverse Event Reporting System, 1999-2012.
    Hoffman KB; Demakas A; Erdman CB; Dimbil M; Doraiswamy PM
    BMJ; 2013 Jul; 347():f4656. PubMed ID: 23881998
    [No Abstract]   [Full Text] [Related]  

  • 51. Droperidol, QT prolongation, and sudden death: what is the evidence?
    Kao LW; Kirk MA; Evers SJ; Rosenfeld SH
    Ann Emerg Med; 2003 Apr; 41(4):546-58. PubMed ID: 12658255
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Preventing postmarketing changes in recommended doses and marketing withdrawals.
    Peck C
    Ernst Schering Res Found Workshop; 2007; (59):209-16. PubMed ID: 17117726
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Vaccination policies and programs: the federal government's role in making the system work.
    Schwartz B; Orenstein WA
    Prim Care; 2001 Dec; 28(4):697-711, v. PubMed ID: 11739026
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Safety, scrutiny and conflicts: assessing the fallout and lessons learned from pharmaceuticals.
    Lanzafame RJ
    Photomed Laser Surg; 2005 Feb; 23(1):1-2. PubMed ID: 15782023
    [No Abstract]   [Full Text] [Related]  

  • 55. MedWatch: FDA's new medical products reporting program.
    Kessler DA; Kennedy DL
    J Clin Eng; 1993; 18(6):489-92. PubMed ID: 10130858
    [No Abstract]   [Full Text] [Related]  

  • 56. How the US drug safety system should be changed.
    Strom BL
    JAMA; 2006 May; 295(17):2072-5. PubMed ID: 16670415
    [No Abstract]   [Full Text] [Related]  

  • 57. Pin the tail on the other donkey: allocating and avoiding injury losses after drug or device approval.
    O'Reilly JT
    Food Drug Law J; 2007; 62(3):559-72. PubMed ID: 17915397
    [No Abstract]   [Full Text] [Related]  

  • 58. Reporting of adverse drug events: a key to postmarketing drug safety.
    Rheinstein PH
    Am Fam Physician; 1992 Sep; 46(3):873-4. PubMed ID: 1514478
    [No Abstract]   [Full Text] [Related]  

  • 59. MEDWatch: medical products reporting program.
    Minarik PA
    Clin Nurse Spec; 1994 Mar; 8(2):74, 68. PubMed ID: 7882246
    [No Abstract]   [Full Text] [Related]  

  • 60. How pharmaceuticals are developed.
    Vander Elst E
    J Am Dent Assoc; 1994 Jan; 125 Suppl():40S-44S. PubMed ID: 8294674
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.